Experienced in Olfactory Neuroblastoma

Ase Bratland

Oslo, NO 
Experienced in Olfactory Neuroblastoma
Oslo, NO 
OverviewLocationsClinical Research

Overview

Ase Bratland practices in Oslo, Norway. Bratland is rated as an Experienced expert by MediFind in the treatment of Olfactory Neuroblastoma. Their top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Olfactory Neuroblastoma, Adenoid Cystic Carcinoma, and Neuroendocrine Tumor.

Their clinical research consists of co-authoring 26 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Olfactory Neuroblastoma.

Locations

Oslo, Norway
Other Locations
Nydalen, Norway
Norway

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

REPORT; REirradiation and PD-1 Blockade On Recurrent Squamous Cell Head and Neck Tumors
REPORT; REirradiation and PD-1 Blockade On Recurrent Squamous Cell Head and Neck Tumors
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Radiation, Drug
Study Drug: Nivolumab
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
View 1 Less Clinical Trial

26 Total Publications

DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck.
DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: December 28, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Bratland's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile